Study explores the history and current state of psychedelic research for treating substance abuse disorders, highlighting challenges like restrictive policies, lack of funding, and the need for recognition of traditional and modern therapeutic practices.
Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand | Psychedelic Invest
Vancouver, British Columbia–(Newsfile Corp. – January 13, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a Health Canada-licensed
January 17, 2025